Forma Therapeutics, Inc.
Clinical trials sponsored by Forma Therapeutics, Inc., explained in plain language.
A biopharmaceutical company developing therapies for rare diseases and cancer, acquired by Novo Nordisk.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill could shield kids with sickle cell from stroke Results expected Aug 2027 (estimated) May already have reported ↗
-
New daily pill could ease sickle cell pain for kids
Disease control Recruiting nowThis study tests a once-daily pill called etavopivat in children (6 months to 18 years) with sickle cell disease. The main goals are to check safety and how the drug works in the body, and to see if it can raise hemoglobin levels and reduce painful crises. About 95 children will …
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill could shield kids with sickle cell from stroke
Disease control Recruiting nowThis study tests a new medicine called etavopivat in 27 children aged 12-16 with sickle cell disease who are at higher risk for stroke. Participants take one daily pill for a year, and doctors use ultrasound to measure blood flow in the brain. The goal is to see if etavopivat can…
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC